Skip to main content

Gammagard liquid

Pronunciation: Gam-a-gard Lick-wid
Generic name: Immune Globulin Infusion [Human] 10%
Dosage form: liquid for intravenous or subcutaneous infusion
Drug class: Immune globulins

Medically reviewed by Carmen Pope, BPharm. Last updated on Feb 8, 2024.

What is Gammagard liquid?

Gammagard liquid (Immune Globulin Infusion [Human] 10%) is a ready-to-use liquid medicine that contains immunoglobulin G (IgG) antibodies, which protect the body against infection. It may be given as:

Gammagard liquid was FDA approved on April 27, 2005.


There is a risk of thrombosis with immune globulin products, including Gammagard liquid. The risk is higher in older people and in those with prolonged immobilization, hypercoagulable conditions, a history of venous or arterial thrombosis, indwelling vascular catheters, hyperviscosity, cardiovascular risk factors, or using estrogens. For those at risk of thrombosis, ensure they are hydrated before administration and administer Gammagard at the minimum dose and infusion rate. Monitor for signs and symptoms of thrombosis and assess blood viscosity for those at risk.

May cause serious hypersensitivity reactions. Do not use in patients with a history of anaphylactic or severe allergic reactions to human immune globulin. Contraindicated in IgA deficient patients with antibodies to IgA.

Kidney problems including renal dysfunction, acute renal failure, osmotic nephrosis, and death may occur in predisposed patients with immune globulin intravenous (IGIV) products including Gammagard liquid, especially those that contain sucrose. Gammagard liquid does not contain sucrose. Your healthcare provider will monitor your renal function, including blood urea nitrogen, serum creatinine, and urine output if you are at risk.

May also increase the risk of high serum protein levels (hyperproteinemia), and low sodium levels (hyponatremia) and increase the viscosity of serum. Aseptic Meningitis Syndrome (AMS), pulmonary adverse reactions, and hemolytic anemia can develop. Your healthcare provider will monitor you for these.

Because Gammagard liquid is made from human blood, it may carry a risk of transmitting infectious agents, such as viruses or Creutzfeldt-Jakob disease variants or agents.

The safety and effectiveness of Gammagard liquid has not been studied in:

Before taking

Tell your healthcare provider if you have a known history of a severe allergic reaction to immune globulin or other blood products or a condition called selective (or severe) immunoglobulin A (IgA) deficiency.

Also, tell your healthcare provider if you:


It is not known if Gammagard liquid can cause fetal harm when administered to a pregnant woman or can affect reproduction capacity. Immune globulins cross the placenta from maternal circulation increasingly after 30 weeks of gestation. Gammagard liquid should be given to a pregnant woman only if clearly indicated.


There is no information regarding the presence of Gammagard liquid in human milk, its effects on the breastfed infant, or its effects on milk production. The developmental and health benefits of breastfeeding should be considered along with the mother’s clinical need for Gammagard liquid and any potential adverse effects on the breastfed infant.

How should I use Gammagard liquid?

Gammagard liquid may be given into a vein (intravenously [IV]) or under the skin (subcutaneously [SC]).

IV infusions are usually given by a healthcare provider in a hospital or infusion center, although sometimes people can be taught how to give themselves an infusion. SC infusions are usually given at home by patients or caregivers. Only use Gammagard liquid by yourself after you have been instructed by your healthcare provider.

What happens if I miss a dose?

If you miss a dose, administer the missed dose as soon as possible, and then resume your regular scheduled treatment.

What happens if I overdose?

With IV administration, an overdose of Gammagard liquid may lead to fluid overload and high serum viscosity. The risk increases in patients of an older age or with cardiac or renal impairment.

What are the side effects of Gammagard liquid?

Gammagard liquid can cause serious side effects including:

If any of the following problems occur after starting treatment with Gammagard liquid, stop the infusion immediately and contact your healthcare provider or call emergency services. These could be signs of a serious problem.

The following one or more possible reactions may occur after the administration of Gammagard. These generally go away within a few hours and are less likely after the first few infusions.

The most common side effects observed in 5% or more patients when given either intravenously or subcutaneously include:

These are not all of the possible side effects of Gammagard liquid. You can ask your healthcare provider for a physician’s information leaflet. Tell your healthcare provider about any side effect that bothers you or that does not go away.

Whenever giving yourself treatments at home, you should have another responsible person present to help treat side effects or get help if you have a serious adverse reaction occur. Ask your healthcare provider whether you should have rescue medications, such as antihistamines or epinephrine.

To report suspected adverse reactions, contact Takeda Pharmaceuticals U.S.A., Inc. at 1-877-TAKEDA-7 (1-877-825-3327) or the FDA at 1-800-FDA-1088 or

What should I avoid while receiving Gammagard liquid?

Gammagard liquid can make vaccines (like measles/mumps/rubella or chickenpox vaccines) not work as well for you. Before you get any vaccines, tell your healthcare provider that you take Gammagard liquid.


Store vials in their original boxes to protect them from light. Do not freeze. Store in the refrigerator or at room temperature.

Expiration dates for both storage conditions are printed on the outer carton and vial label. Do not use past the applicable expiration date.


Active: Human Immunoglobulin G.

Inactive: Glycine.

Not made with natural rubber latex.

Made from human plasma donated by healthy people.




  1. FDA Package Insert

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.